血必净注射液治疗脓毒症的疗效与安全性:随机对照试验的荟萃分析
该系统评价纳入16项随机对照试验共1144例脓毒症患者,评估血必净注射液联合常规治疗对比单用常规治疗的疗效与安全性。中等质量证据显示联合治疗可降低28天死亡率(RR 0.62,95%CI 0.51-0.76)、APACHEⅡ评分和体温,但治疗期间死亡率无显著差异,且因纳入试验质量偏低,尚不能得出常规使用结论。
要点
- 血必净联合常规治疗可能降低脓毒症患者28天死亡率(RR 0.62,95%CI 0.51-0.76)。
- 联合治疗可改善APACHEⅡ评分和体温,但治疗期间死亡率无显著降低。
- 证据质量多为低至中等,且存在高偏倚风险,需更多高质量试验验证。
核心结论
- 血必净注射液联合常规治疗可能改善脓毒症患者的28天死亡率、APACHEⅡ评分、白细胞计数和体温,且未报告严重不良事件,但可能不降低治疗期间死亡率,提示中药的特定远期效应。
- 鉴于纳入试验的高偏倚风险和低质量证据,尚不能对其常规使用得出结论,需要严格设计的多中心大规模试验。
研究设计与样本
- 系统评价与荟萃分析,检索Embase、PubMed、Cochrane Central Register of Controlled Trials、CNKI、VIP和万方数据库自建库至2017年6月6日的文献。
- 纳入16项随机对照试验,共1144例脓毒症患者,比较血必净联合常规治疗与单用常规治疗,排除Jadad评分<3的低质量研究。
主要发现
- 低质量证据显示治疗期间死亡率无风险差异(210/1144,RR 0.65,95%CI 0.36-1.17,P=0.15,I²=0%)。
关键数值与推荐
- 主要临床结局为28天死亡率和治疗期间死亡率,次要结局包括APACHEⅡ评分、白细胞计数、体温和不良事件或反应。
- 采用固定效应模型计算主要结局的风险比(RR),并使用GRADE方法评估证据质量。
临床怎么用
- 在常规治疗基础上加用血必净注射液可能有助于改善脓毒症患者的28天死亡率、APACHEⅡ评分和体温,但需谨慎对待证据质量。
- 因证据质量偏低且存在高偏倚风险,不应将血必净作为脓毒症的常规推荐,临床决策应个体化并关注剂量效应关系与安全性。
局限性
- 纳入试验存在高偏倚风险且整体质量偏低,部分结局证据质量极低。
- 剂量效应关系和安全性的研究数量不足,需更多高质量试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Xuebijing injection (XBJ), a Chinese patent medicine that was approved for treating sepsis in China in 2004, consists of Carthamus tinctorius L. (Carthami Flos, hong hua), Paeonia lactiflora Pall. (Paeoniae Radix Rubra, chi shao), Ligusticum chuanxiong Hort. (Chuanxiong Rhizoma, chuan xiong), Salvia miltiorrhiza Bge. (Salviae Miltiorrhizae Radix Et Rhizoma, dan shen) and Angelica sinensis (Oliv.) Diels (Angelicae Sinensis Radix, dang gui). AIM OF THE STUDY: This study aimed to assess the efficacy and safety of XBJ combined with routine treatment (RT) for treating sepsis through systematic review and meta-analysis. MATERIALS AND METHODS: Databases including Embase, PubMed, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Journal Database (VIP) and the Wanfang database were searched from inception to June 6, 2017 to collect relevant RCTs comparing XBJ combined with RT and RT alone for sepsis. The primary clinical outcomes were 28-day mortality and mortality during treatment. The secondary outcomes of our study included APACHE Ⅱ scores, WBC counts, body temperature, and adverse events or reactions. We excluded low-quality studies (Jadad score < 3) and calculated risk ratios (RR) for primary outcomes with fixed effects models. We assessed quality of evidence using the grading of recommendations assessment, development, and evaluation (GRADE) approach. RESULTS: We identified 1602 records, and 16 RCTs (1144 patients) were included. Moderate-quality evidence suggested that combined therapy reduced 28-day mortality (934/1144, RR 0.62, 95% CI 0.51-0.76 P < 0.000 01, I2 = 0%), APACHE Ⅱ scores (792/1144, MD -3.53, 95% CI -4.49 to -2.54; P < 0.000 01, I2 = 59%) and body temperature (362/1144, MD -0.43, 95% CI -0.55 to -0.31; P < 0.000 01, I2 = 0%). Very low-quality evidence showed that WBC count improved with combined medication at high dosages (one study included, 40/1144, MD -8.00, 95% CI -10.18 to -5.82), but there was no reduction at moderate dosages (230/1144, MD -2.38, 95% CI -5.01 to 0.25; P = 0.08, I2 = 70%). However, moderate-quality evidence indicated positive results with low dosages (142/1144, MD -2.88, 95% CI -3.79 to -1.96; P < 0.000 01, I2 = 0%). Nevertheless, due to the insufficient number of studies and the poor quality of the current evidence, more studies of dose-effect relationships and safety concerns of XBJ are needed. Low-quality evidence showed no risk difference for mortality during treatment (210/1144, RR 0.65, 95% CI 0.36-1.17; P = 0.15, I2 = 0%). CONCLUSIONS: This study suggested that supplementation with XBJ in addition to regular treatment may improve the 28-day mortality rate, APACHE Ⅱ scores, WBC count and body temperature of sepsis patients without serious adverse events, but it may not reduce mortality during treatment, revealing a specific, remote effect of traditional Chinese medicine. However, given the high risk of bias and the low quality of the included trials, we may be unable to draw any conclusions about its routine use. Rigorously designed, multicentre, large-scale, methodologically sound trials are warranted.
引用
- Li C, Wang P, Zhang L, et al. Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: A meta-analysis of randomized controlled trials. J Ethnopharmacol. 2018. PMID: 29860133. doi:10.1016/j.jep.2018.05.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。